Abstract:
Objective To investigate the clinical study of low molecular weight heparin sodium and warfarin combined with aspirin on left atrial thrombus disrupting cerebral embolism in patients with rheumatic heart disease.
Methods From December 2013 to December 2016, 56 patients with rheumatic heart disease in the Jiaozhou People′s Hospital were randomly divided into control group and study group (n=28), the control group was treated with aspirin, and the study group was treated with low molecular weight heparin + warfarin + aspirin. Treatment effect, coagulation function changes prothrombin activity (PA), partial prothrombin time (PT), platelet aggregation rate (PAR), activated partial thrombin time (APTT) were statistically compared between the two groups.
Results The effective rate in the study group (92.86%) was higher than in the control group (64.29%), the difference was statistically significant (P<0.05); PAR, PT and APTT after treatment were higher than those before treatment, PAR was lower than before treatment, and PAR in the study group was lower than that in the control group, the difference was statistically significant (P<0.05); There was no significant difference in the incidence of adverse reactions between the study group (17.85%) and the control group (25.00%) (P>0.05).
Conclusion Low molecular weight heparin and warfarin combined with aspirin is significantly effective in the treatment of rheumatic heart disease with left atrial thrombus for cerebral embolism, and the safety is high.
Key words:
Low molecular weight heparin sodium,
Warfarin,
Aspirin,
Rheumatic heart disease,
Thrombus detachment cerebral embolism
Dunyan Leng, Jihong Ma. Clinical study of low molecular weight heparin sodium and warfarin combined with aspirin on left atrial thrombus disrupting cerebral embolism in patients with rheumatic heart disease[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2017, 05(01): 12-14.